Patents by Inventor Rogier Christian Buijsman
Rogier Christian Buijsman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11053230Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: GrantFiled: August 30, 2018Date of Patent: July 6, 2021Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 10689343Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.Type: GrantFiled: July 11, 2017Date of Patent: June 23, 2020Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20200181128Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: ApplicationFiled: August 30, 2018Publication date: June 11, 2020Applicant: Netherlands Translational Research Center B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 10494360Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: GrantFiled: March 8, 2017Date of Patent: December 3, 2019Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.VInventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20190315688Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.Type: ApplicationFiled: July 11, 2017Publication date: October 17, 2019Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20190055213Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: ApplicationFiled: March 8, 2017Publication date: February 21, 2019Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius DE MAN, Joost Cornelis Marinus UITDEHAAG, Jan Gerard STERRENBURG, Joeri Johannes Petrus DE WIT, Nicole Wilhelmina Cornelia SEEGERS, Antonius Maria VAN DOORNMALEN, Rogier Christian BUIJSMAN, Guido Jenny Rudolf ZAMAN
-
Patent number: 9856258Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: GrantFiled: March 30, 2015Date of Patent: January 2, 2018Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman
-
Publication number: 20170096432Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: ApplicationFiled: March 30, 2015Publication date: April 6, 2017Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius DE MAN, Rogier Christian BUIJSMAN, Jan Gerard STERRENBURG, Joost Cornelis Marinus UITDEHAAG, Joeri Johannes Petrus DE WIT, Guido Jenny Rudolf ZAMAN
-
Publication number: 20140155406Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds of formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.Type: ApplicationFiled: July 11, 2012Publication date: June 5, 2014Inventors: Petrus Antonius De Adrianus Man, Jacobus C.H.M. Wijkmans, Jan-Gerard Sterrenburg, Han C.A. Raaijmakers, Tjeerd A. Barf, Rogier Christian Buijsman, Arthur A. Oubrie, Johannes Bernardus Maria Rewinkel, Christiaan Gerardus Johannes Maria Jans, Herman Thijs Stock
-
Patent number: 8133885Abstract: The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of these derivatives to modulate glucocorticoid receptor activity.Type: GrantFiled: February 14, 2006Date of Patent: March 13, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Ralf Plate, Guido Jenny Rudolf Zaman, Pedro Harold Han Hermkens, Christiaan Gerardus Johannes Maria Jans, Rogier Christian Buijsman, Adrianus Petrus Antonius De Man, Paolo Giovanni Martino Conti, Scott James Lusher, Willem Hendrik Abraham Dokter
-
Patent number: 7576071Abstract: The present invention relates compounds of the formula A oligosaccharide-spacer-GpIIb/IIIa antagonist ??(A). The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases.Type: GrantFiled: August 31, 2006Date of Patent: August 18, 2009Assignee: sanofi-aventisInventors: Rogier Christian Buijsman, Martin De Kort, Dirk Gerrit Meuleman, Constant Van Boeckel
-
Publication number: 20090062262Abstract: The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 14, 2006Publication date: March 5, 2009Applicant: N.V. ORGANONInventors: Ralf Plate, Guido Jenny Rudolf Zaman, Pedro Harold Han Hermkens, Christiaan Gerardus Johannes Maria Jans, Rogier Christian Buijsman, Adrianus Petrus Antonius De Man, Paolo Giovanni Martino Conti, Scott James Lusher, Willem Hendrik Abraham Dokter
-
Patent number: 6486129Abstract: The present invention relates to compounds of formula (1), wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substitutents selected from (1-8C)alkyl or (1-8C)alkoxy; R2 and R3 are independently H or (1-8C)alkyl; R4 is (1-8C)alkyl or (3-8C)cycloalkyl; or R3 and R4 together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO2-(1-8C)alkyl; Q is a spacer having a chain length of 10 to 70 atoms; and Z is a negatively charged oligosaccharide residue comprising two to six monosaccharide units, the charge being compensated by positively charged counterions; or a pharmaceutically acceptable salt thereof or a prodrug thereof.Type: GrantFiled: December 18, 2000Date of Patent: November 26, 2002Assignees: Akzo Nobel N.V., University LeidenInventors: Cornelia Maria Tromp, Johannes Egbertus Maria Basten, Constant Adriaan Anton van Boeckel, Rogier Christian Buijsman
-
Patent number: RE48974Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: GrantFiled: December 27, 2019Date of Patent: March 15, 2022Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman